Intravenous	intravenous	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
for	for	O	O	O	O
severe	severe	O	O	O	O
adenovirus	adenovirus	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
in	in	O	O	O	O
immunocompromised	immunocompromised	O	O	O	O
children	children	O	O	O	O
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Adenovirus	adenovirus	O	O	O	O
is	is	O	O	O	O
an	an	O	O	O	O
important	important	O	O	O	O
cause	cause	O	O	O	O
of	of	O	O	O	O
morbidity	morbidity	O	O	O	O
and	and	O	O	O	O
mortality	mortality	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
immunocompromised	immunocompromised	O	O	O	O
host	host	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
severe	severe	O	O	O	O
adenovirus	adenovirus	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
in	in	O	O	O	O
pediatrics	pediatrics	O	O	O	O
is	is	O	O	O	O
increasing	increasing	O	O	O	O
in	in	O	O	O	O
association	association	O	O	O	O
with	with	O	O	O	O
growing	growing	O	O	O	O
numbers	numbers	O	O	O	O
of	of	O	O	O	O
immunocompromised	immunocompromised	O	O	O	O
children	children	O	O	O	O
,	,	O	O	O	O
where	where	O	O	O	O
case	case	O	O	O	O
fatality	fatality	O	O	O	O
rates	rates	O	O	O	O
as	as	O	O	O	O
high	high	O	O	O	O
as	as	O	O	O	O
50	50	O	O	O	O
%	%	O	O	O	O
to	to	O	O	O	O
80	80	O	O	O	O
%	%	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
are	are	O	O	O	O
no	no	O	O	O	O
approved	approved	O	O	O	O
antiviral	antiviral	CHEMICALS	O	OTHERS	I
agents	agents	CHEMICALS	O	OTHERS	I
with	with	O	O	O	O
proven	proven	O	O	O	O
efficacy	efficacy	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
severe	severe	O	O	O	O
adenovirus	adenovirus	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
,	,	O	O	O	O
nor	nor	O	O	O	O
are	are	O	O	O	O
there	there	O	O	O	O
any	any	O	O	O	O
prospective	prospective	O	O	O	O
randomized	randomized	O	O	O	O
,	,	O	O	O	O
controlled	controlled	O	O	O	O
trials	trials	O	O	O	O
of	of	O	O	O	O
potentially	potentially	O	O	O	O
useful	useful	O	O	O	O
anti-adenovirus	anti-adenovirus	O	O	O	O
therapies	therapies	O	O	O	O
.	.	O	O	O	O

Apparent	apparent	O	O	O	O
clinical	clinical	O	O	O	O
success	success	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
severe	severe	O	O	O	O
adenovirus	adenovirus	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
is	is	O	O	O	O
limited	limited	O	O	O	O
to	to	O	O	O	O
a	a	O	O	O	O
few	few	O	O	O	O
case	case	O	O	O	O
reports	reports	O	O	O	O
and	and	O	O	O	O
small	small	O	O	O	O
series	series	O	O	O	O
.	.	O	O	O	O

Experience	experience	O	O	O	O
is	is	O	O	O	O
greatest	greatest	O	O	O	O
with	with	O	O	O	O
intravenous	intravenous	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
cidofovir	cidofovir	O	O	OTHERS	I
.	.	O	O	O	O

Ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
guanosine	guanosine	O	O	OTHERS	I
analogue	analogue	O	O	O	O
,	,	O	O	O	O
has	has	O	O	O	O
broad	broad	O	O	O	O
antiviral	antiviral	O	O	O	O
activity	activity	O	O	O	O
against	against	O	O	O	O
both	both	O	O	O	O
RNA	rna	O	O	O	O
and	and	O	O	O	O
DNA	dna	O	O	O	O
viruses	viruses	O	O	O	O
,	,	O	O	O	O
including	including	O	O	O	O
documented	documented	O	O	O	O
activity	activity	O	O	O	O
against	against	O	O	O	O
adenovirus	adenovirus	O	O	O	O
in	in	O	O	O	O
vitro	vitro	O	O	O	O
.	.	O	O	O	O

Ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
licensed	licensed	O	O	O	O
in	in	O	O	O	O
aerosol	aerosol	O	O	O	O
form	form	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
respiratory	respiratory	O	O	OTHERS	I
syncytial	syncytial	O	O	OTHERS	I
virus	virus	O	O	OTHERS	I
infection	infection	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
orally	orally	O	O	O	O
in	in	O	O	O	O
combination	combination	O	O	O	O
with	with	O	O	O	O
interferon	interferon	O	O	OTHERS	I
to	to	O	O	O	O
treat	treat	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
C.	c.	O	O	O	O
Intravenous	intravenous	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
choice	choice	O	O	O	O
for	for	O	O	O	O
infection	infection	O	DISEASE	OTHERS	I
with	with	O	O	OTHERS	I
hemorrhagic	hemorrhagic	O	DISEASE	OTHERS	I
fever	fever	O	DISEASE	OTHERS	I
viruses	viruses	O	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
most	most	O	O	O	O
common	common	O	O	O	O
adverse	adverse	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
intravenous	intravenous	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
reversible	reversible	O	O	O	O
mild	mild	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
cidofovir	cidofovir	O	O	OTHERS	I
in	in	O	O	O	O
severe	severe	O	O	O	O
adenovirus	adenovirus	O	O	OTHERS	I
infection	infection	O	DISEASE	OTHERS	I
has	has	O	O	O	O
been	been	O	O	O	O
limited	limited	O	O	O	O
by	by	O	O	O	O
adverse	adverse	O	O	O	O
effects	effects	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
most	most	O	O	O	O
significant	significant	O	O	O	O
of	of	O	O	O	O
which	which	O	O	O	O
is	is	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
We	we	O	O	O	O
report	report	O	O	O	O
our	our	O	O	O	O
experience	experience	O	O	O	O
with	with	O	O	O	O
intravenous	intravenous	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
for	for	O	O	O	O
severe	severe	O	O	O	O
adenovirus	adenovirus	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
series	series	O	O	O	O
of	of	O	O	O	O
immunocompromised	immunocompromised	O	O	O	O
children	children	O	O	O	O
and	and	O	O	O	O
review	review	O	O	O	O
the	the	O	O	O	O
literature	literature	O	O	O	O
.	.	O	O	O	O

DESIGN/METHODS	design/methods	O	O	O	O
:	:	O	O	O	O
We	we	O	O	O	O
retrospectively	retrospectively	O	O	O	O
reviewed	reviewed	O	O	O	O
the	the	O	O	O	O
medical	medical	O	O	O	O
records	records	O	O	O	O
of	of	O	O	O	O
5	5	O	O	O	O
children	children	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
intravenous	intravenous	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
documented	documented	O	O	O	O
severe	severe	O	O	O	O
adenovirus	adenovirus	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
.	.	O	O	O	O

Two	two	O	O	O	O
patients	patients	O	O	O	O
developed	developed	O	O	O	O
adenovirus	adenovirus	O	O	O	O
hemorrhagic	hemorrhagic	O	DISEASE	OTHERS	I
cystitis	cystitis	O	DISEASE	OTHERS	I
after	after	O	O	O	O
cardiac	cardiac	O	O	O	O
and	and	O	O	O	O
bone	bone	O	O	O	O
marrow	marrow	O	O	O	O
transplants	transplants	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
bone	bone	O	O	O	O
marrow	marrow	O	O	O	O
transplant	transplant	O	O	O	O
patient	patient	O	O	O	O
also	also	O	O	O	O
received	received	O	O	O	O
intravenous	intravenous	O	O	O	O
cidofovir	cidofovir	O	O	OTHERS	I
for	for	O	O	O	O
progressive	progressive	O	O	O	O
disseminated	disseminated	O	O	O	O
disease	disease	O	O	O	O
.	.	O	O	O	O

An	an	O	O	O	O
additional	additional	O	O	O	O
3	3	O	O	O	O
children	children	O	O	O	O
developed	developed	O	O	O	O
adenovirus	adenovirus	O	O	O	O
pneumonia	pneumonia	O	O	OTHERS	I
;	;	O	O	O	O
2	2	O	O	O	O
were	were	O	O	O	O
neonates	neonates	O	O	O	O
,	,	O	O	O	O
1	1	O	O	O	O
of	of	O	O	O	O
whom	whom	O	O	O	O
had	had	O	O	O	O
partial	partial	O	O	O	O
DiGeorge	digeorge	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
remaining	remaining	O	O	O	O
infant	infant	O	O	O	O
had	had	O	O	O	O
recently	recently	O	O	O	O
undergone	undergone	O	O	O	O
a	a	O	O	O	O
cardiac	cardiac	O	O	O	O
transplant	transplant	O	O	O	O
.	.	O	O	O	O

Intravenous	intravenous	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
administered	administered	O	O	O	O
on	on	O	O	O	O
a	a	O	O	O	O
compassionate-use	compassionate-use	O	O	O	O
protocol	protocol	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Complete	complete	O	O	O	O
clinical	clinical	O	O	O	O
recovery	recovery	O	O	O	O
followed	followed	O	O	O	O
later	later	O	O	O	O
by	by	O	O	O	O
viral	viral	O	O	O	O
clearance	clearance	O	O	O	O
was	was	O	O	O	O
observed	observed	O	O	O	O
in	in	O	O	O	O
2	2	O	O	O	O
children	children	O	O	O	O
:	:	O	O	O	O
the	the	O	O	O	O
cardiac	cardiac	O	O	O	O
transplant	transplant	O	O	O	O
recipient	recipient	O	O	O	O
with	with	O	O	O	O
adenovirus	adenovirus	O	O	O	O
hemorrhagic	hemorrhagic	O	DISEASE	OTHERS	I
cystitis	cystitis	O	DISEASE	OTHERS	I
and	and	O	O	O	O
the	the	O	O	O	O
immunocompetent	immunocompetent	O	O	O	O
neonate	neonate	O	O	O	O
with	with	O	O	O	O
adenovirus	adenovirus	O	O	O	O
pneumonia	pneumonia	O	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
remaining	remaining	O	O	O	O
3	3	O	O	O	O
children	children	O	O	O	O
died	died	O	O	O	O
of	of	O	O	O	O
adenovirus	adenovirus	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
.	.	O	O	O	O

Intravenous	intravenous	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
was	was	O	O	O	O
well	well	O	O	O	O
tolerated	tolerated	O	O	O	O
.	.	O	O	O	O

Use	use	O	O	O	O
of	of	O	O	O	O
cidofovir	cidofovir	O	O	OTHERS	I
in	in	O	O	O	O
1	1	O	O	O	O
child	child	O	O	O	O
was	was	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
progressive	progressive	O	O	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
and	and	O	O	O	O
neutropenia	neutropenia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

DISCUSSION	discussion	O	O	O	O
:	:	O	O	O	O
Our	our	O	O	O	O
series	series	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
is	is	O	O	O	O
representative	representative	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
spectrum	spectrum	O	O	O	O
of	of	O	O	O	O
immunocompromised	immunocompromised	O	O	O	O
children	children	O	O	O	O
at	at	O	O	O	O
greatest	greatest	O	O	O	O
risk	risk	O	O	O	O
for	for	O	O	O	O
severe	severe	O	O	O	O
adenovirus	adenovirus	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
,	,	O	O	O	O
namely	namely	O	O	O	O
solid-organ	solid-organ	O	O	O	O
and	and	O	O	O	O
bone	bone	O	O	O	O
marrow	marrow	O	O	O	O
transplant	transplant	O	O	O	O
recipients	recipients	O	O	O	O
,	,	O	O	O	O
neonates	neonates	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
children	children	O	O	O	O
with	with	O	O	O	O
immunodeficiency	immunodeficiency	O	O	OTHERS	I
.	.	O	O	O	O

Although	although	O	O	O	O
intravenous	intravenous	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
not	not	O	O	O	O
effective	effective	O	O	O	O
for	for	O	O	O	O
all	all	O	O	O	O
children	children	O	O	O	O
with	with	O	O	O	O
severe	severe	O	O	O	O
adenovirus	adenovirus	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
in	in	O	O	O	O
this	this	O	O	O	O
series	series	O	O	O	O
or	or	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
literature	literature	O	O	O	O
,	,	O	O	O	O
therapy	therapy	O	O	O	O
is	is	O	O	O	O
unlikely	unlikely	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
of	of	O	O	O	O
benefit	benefit	O	O	O	O
if	if	O	O	O	O
begun	begun	O	O	O	O
late	late	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
course	course	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
infection	infection	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Early	early	O	O	O	O
identification	identification	O	O	O	O
,	,	O	O	O	O
eg	eg	O	O	O	O
by	by	O	O	O	O
polymerase	polymerase	O	O	O	O
chain	chain	O	O	O	O
reaction	reaction	O	O	O	O
of	of	O	O	O	O
those	those	O	O	O	O
patients	patients	O	O	O	O
at	at	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
disseminated	disseminated	O	O	O	O
adenovirus	adenovirus	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
may	may	O	O	O	O
permit	permit	O	O	O	O
earlier	earlier	O	O	O	O
antiviral	antiviral	O	O	O	O
treatment	treatment	O	O	O	O
and	and	O	O	O	O
better	better	O	O	O	O
evaluation	evaluation	O	O	O	O
of	of	O	O	O	O
therapeutic	therapeutic	O	O	O	O
response	response	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
Two	two	O	O	O	O
of	of	O	O	O	O
5	5	O	O	O	O
children	children	O	O	O	O
with	with	O	O	O	O
severe	severe	O	O	O	O
adenovirus	adenovirus	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
treated	treated	O	O	O	O
with	with	O	O	O	O
intravenous	intravenous	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
recovered	recovered	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
availability	availability	O	O	O	O
of	of	O	O	O	O
newer	newer	O	O	O	O
rapid	rapid	O	O	O	O
diagnostic	diagnostic	O	O	O	O
techniques	techniques	O	O	O	O
,	,	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
polymerase	polymerase	O	O	O	O
chain	chain	O	O	O	O
reaction	reaction	O	O	O	O
,	,	O	O	O	O
may	may	O	O	O	O
make	make	O	O	O	O
earlier	earlier	O	O	O	O
,	,	O	O	O	O
more	more	O	O	O	O
effective	effective	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
adenovirus	adenovirus	O	O	OTHERS	I
infection	infection	O	DISEASE	OTHERS	I
possible	possible	O	O	O	O
.	.	O	O	O	O

Given	given	O	O	O	O
the	the	O	O	O	O
seriousness	seriousness	O	O	O	O
and	and	O	O	O	O
increasing	increasing	O	O	O	O
prevalence	prevalence	O	O	O	O
of	of	O	O	O	O
adenovirus	adenovirus	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
in	in	O	O	O	O
certain	certain	O	O	O	O
hosts	hosts	O	O	O	O
,	,	O	O	O	O
especially	especially	O	O	O	O
children	children	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
large	large	O	O	O	O
,	,	O	O	O	O
multicenter	multicenter	O	O	O	O
clinical	clinical	O	O	O	O
trial	trial	O	O	O	O
of	of	O	O	O	O
potentially	potentially	O	O	O	O
useful	useful	O	O	O	O
anti-adenoviral	anti-adenoviral	O	O	O	O
therapies	therapies	O	O	O	O
,	,	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
intravenous	intravenous	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
is	is	O	O	O	O
clearly	clearly	O	O	O	O
required	required	O	O	O	O
to	to	O	O	O	O
demonstrate	demonstrate	O	O	O	O
the	the	O	O	O	O
most	most	O	O	O	O
effective	effective	O	O	O	O
and	and	O	O	O	O
least	least	O	O	O	O
toxic	toxic	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

